Skip to main content
Independent federal grant matching. Not affiliated with any government agency. Get free access and see which open grants fit your organization.
Closed on Jun 15, 2026

Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers

Food and Drug Administration · Opportunity number RFA-FD-26-004

View the official notice on Grants.gov

Details summarized from the official notice as of Jun 16, 2026. Always confirm eligibility, deadlines and requirements in the official notice before applying.

Independent platform. Not affiliated with or endorsed by any government agency. Data from public federal sources.

This opportunity is closed as of Jun 15, 2026. It is kept here for reference. See the related open opportunities below, or check the official listing in case the agency posts a new cycle.

Key facts

Opportunity numberRFA-FD-26-004
AgencyFood and Drug Administration
Department of Health and Human Services
Assistance listing (ALN, formerly CFDA)93.103
PostedMay 4, 2026
DeadlineJun 15, 2026
Award ceiling$500,000
Expected number of awards3
Estimated total program funding$1,500,000
Cost sharing or matching requiredNo
Funding typeCooperative agreement
CategoryAgriculture
Last updated hereJun 16, 2026

Summary from the notice

Background

The FDA Oncology Center of Excellence (OCE) aims to advance the development and regulation of oncology products for patients with cancer. The Pediatric Oncology Program and Rare Cancers Program were established to facilitate and expedite drug development for pediatric and other rare cancers. OCE’s Project Catalyst connects scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation, which is particularly important to address the challenges related to product development for ultra-rare cancers. In collaboration with the National Institutes of Health (NIH) and the OCE, the Foundation for the National Institutes of Health (FNIH) recently launched the design phase of the Ultra-Rare Cancer Treatment Advancement Program (ULTRA), a new public-private partnership dedicated to accelerating the development of innovative ultra-rare cancer treatments. 

For the purposes of this NOFO, the FDA OCE refers to cancers with an approximate annual incidence in the U.S. of 300 to 400 people or less as ultra-rare (a more stringent criterion compared to the threshold for a rare disease specified in the Orphan Drug Act based on a U.S. prevalence of

Who can apply

The official notice lists these applicant types as eligible:

  • Private colleges and universities
  • Special district governments
  • County governments
  • Federally recognized tribal governments
  • Public and state colleges and universities
  • Other Native American tribal organizations
  • Small businesses
  • Nonprofits without 501(c)(3) status (other than colleges)
  • City or township governments
  • Nonprofits with 501(c)(3) status (other than colleges)
  • For-profit organizations other than small businesses
  • Independent school districts
  • Public and Indian housing authorities
  • State governments

Who should take a closer look

  • Small businesses
  • Nonprofits
  • Colleges and universities
  • State governments
  • Local governments
  • Tribal governments and organizations
  • Larger for-profit companies

Not listed as eligible

  • Individuals

Unless the eligibility text in the notice names you, this opportunity is probably not for you.

Registrations you will likely need

Most applications submitted through Grants.gov need the following. Registration can take several weeks, so start early. The notice lists the exact requirements.

Related open opportunities

Minor Use Minor Species Development of Drugs (R01)

Food and Drug Administration · PAR-24-216

Deadline: Jan 29, 2027 (105 days left) Up to: $250,000 Consumer protection

Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed

Food and Drug Administration · PAR-25-003

Deadline: Apr 1, 2027 (167 days left) Health

NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens

Food and Drug Administration · PAR-25-014

Deadline: Apr 1, 2027 (167 days left) Up to: $200,000 Agriculture

Laboratory Flexible Funding Model (LFFM)

Food and Drug Administration · RFA-FD-25-007

Deadline: Jan 11, 2028 (452 days left) Up to: $1,500,000 Agriculture

Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)

Food and Drug Administration · RFA-FD-25-017

Deadline: Feb 8, 2028 (480 days left) Up to: $600,000 Agriculture